Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Nov;47:2299–2304.

Varicella zoster virus. Recent advances in management.

P Rajan 1, J K Rivers 1
PMCID: PMC2018456  PMID: 11768928

Abstract

OBJECTIVE: To provide an update on strategies for managing varicella zoster virus (VZV) and for preventing and treating established postherpetic neuralgia (PHN). QUALITY OF EVIDENCE: Treatment guidelines are based on randomized clinical trials. Recommendations concerning other aspects of VZV management (e.g., vaccination) are based mainly on expert opinion. MAIN MESSAGE: Varicella and herpes zoster caused by VZV can give rise to serious morbidity and mortality and should be treated. For preventing chickenpox, safe and effective immunization is widely recommended. Treating varicella-exposed seronegative pregnant women requires special attention because the virus can harm expectant mothers, fetuses, and newborns. The antiviral drugs, acyclovir, valacyclovir, and famciclovir, have been approved for treating herpes zoster and have a role in reducing the duration of PHN. Established PHN can be managed with analgesics, tricyclic antidepressants, and other agents. CONCLUSION: Vaccination and antiviral and other systemic agents can substantially reduce the morbidity associated with VZV infection.

Full Text

The Full Text of this article is available as a PDF (157.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bean B., Braun C., Balfour H. H., Jr Acyclovir therapy for acute herpes zoster. Lancet. 1982 Jul 17;2(8290):118–121. doi: 10.1016/s0140-6736(82)91090-x. [DOI] [PubMed] [Google Scholar]
  2. Beutner K. R., Friedman D. J., Forszpaniak C., Andersen P. L., Wood M. J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546–1553. doi: 10.1128/aac.39.7.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burnette T. C., de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos. 1994 Jan-Feb;22(1):60–64. [PubMed] [Google Scholar]
  4. Crooks R. J., Jones D. A., Fiddian A. P. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl. 1991;80:62–68. [PubMed] [Google Scholar]
  5. Dunkle L. M., Arvin A. M., Whitley R. J., Rotbart H. A., Feder H. M., Jr, Feldman S., Gershon A. A., Levy M. L., Hayden G. F., McGuirt P. V. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991 Nov 28;325(22):1539–1544. doi: 10.1056/NEJM199111283252203. [DOI] [PubMed] [Google Scholar]
  6. Eaglstein W. H., Katz R., Brown J. A. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA. 1970 Mar 9;211(10):1681–1683. [PubMed] [Google Scholar]
  7. Earnshaw D. L., Bacon T. H., Darlison S. J., Edmonds K., Perkins R. M., Vere Hodge R. A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992 Dec;36(12):2747–2757. doi: 10.1128/aac.36.12.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fife K. H., Barbarash R. A., Rudolph T., Degregorio B., Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis. 1997 Sep;24(8):481–486. doi: 10.1097/00007435-199709000-00007. [DOI] [PubMed] [Google Scholar]
  9. Gershon A. A. Live attenuated varicella vaccine. Annu Rev Med. 1987;38:41–50. doi: 10.1146/annurev.me.38.020187.000353. [DOI] [PubMed] [Google Scholar]
  10. Gershon A. A. Viral vaccines of the future. Pediatr Clin North Am. 1990 Jun;37(3):689–707. doi: 10.1016/s0031-3955(16)36911-5. [DOI] [PubMed] [Google Scholar]
  11. Harding S. P., Porter S. M. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res. 1991;10 (Suppl):177–182. doi: 10.3109/02713689109020376. [DOI] [PubMed] [Google Scholar]
  12. Huff J. C., Bean B., Balfour H. H., Jr, Laskin O. L., Connor J. D., Corey L., Bryson Y. J., McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
  13. Jacobson M. A., Gallant J., Wang L. H., Coakley D., Weller S., Gary D., Squires L., Smiley M. L., Blum M. R., Feinberg J. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 1994 Jul;38(7):1534–1540. doi: 10.1128/aac.38.7.1534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. KRUGMAN S., GOODRICH C. H., WARD R. Primary varicella pneumonia. N Engl J Med. 1957 Oct 31;257(18):843–848. doi: 10.1056/NEJM195710312571801. [DOI] [PubMed] [Google Scholar]
  15. Kost R. G., Straus S. E. Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med. 1996 Jul 4;335(1):32–42. doi: 10.1056/NEJM199607043350107. [DOI] [PubMed] [Google Scholar]
  16. Levin M. J., Barber D., Goldblatt E., Jones M., LaFleur B., Chan C., Stinson D., Zerbe G. O., Hayward A. R. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis. 1998 Nov;178 (Suppl 1):S109–S112. doi: 10.1086/514264. [DOI] [PubMed] [Google Scholar]
  17. McCrary M. L., Severson J., Tyring S. K. Varicella zoster virus. J Am Acad Dermatol. 1999 Jul;41(1):1–16. doi: 10.1016/s0190-9622(99)70398-1. [DOI] [PubMed] [Google Scholar]
  18. McKendrick M. W., McGill J. I., White J. E., Wood M. J. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986 Dec 13;293(6561):1529–1532. doi: 10.1136/bmj.293.6561.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Morton P., Thomson A. N. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989 Mar 8;102(863):93–95. [PubMed] [Google Scholar]
  20. Nyerges G., Meszner Z., Gyarmati E., Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis. 1988 Feb;157(2):309–313. doi: 10.1093/infdis/157.2.309. [DOI] [PubMed] [Google Scholar]
  21. Peterslund N. A., Seyer-Hansen K., Ipsen J., Esmann V., Schonheyder H., Juhl H. Acyclovir in herpes zoster. Lancet. 1981 Oct 17;2(8251):827–830. doi: 10.1016/s0140-6736(81)91102-8. [DOI] [PubMed] [Google Scholar]
  22. Post B. T., Philbrick J. T. Do corticosteroids prevent postherpetic neuralgia? A review of the evidence. J Am Acad Dermatol. 1988 Mar;18(3):605–610. doi: 10.1016/s0190-9622(88)70082-1. [DOI] [PubMed] [Google Scholar]
  23. Prober C. G., Gershon A. A., Grose C., McCracken G. H., Jr, Nelson J. D. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J. 1990 Dec;9(12):865–869. [PubMed] [Google Scholar]
  24. Prober C. G., Kirk L. E., Keeney R. E. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr. 1982 Oct;101(4):622–625. doi: 10.1016/s0022-3476(82)80725-7. [DOI] [PubMed] [Google Scholar]
  25. Pue M. A., Pratt S. K., Fairless A. J., Fowles S., Laroche J., Georgiou P., Prince W. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994 Jan;33(1):119–127. doi: 10.1093/jac/33.1.119. [DOI] [PubMed] [Google Scholar]
  26. Ragozzino M. W., Melton L. J., 3rd, Kurland L. T., Chu C. P., Perry H. O. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982 Sep;61(5):310–316. doi: 10.1097/00005792-198209000-00003. [DOI] [PubMed] [Google Scholar]
  27. Roizman B., Carmichael L. E., Deinhardt F., de-The G., Nahmias A. J., Plowright W., Rapp F., Sheldrick P., Takahashi M., Wolf K. Herpesviridae. Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on Taxonomy of Viruses. Intervirology. 1981;16(4):201–217. doi: 10.1159/000149269. [DOI] [PubMed] [Google Scholar]
  28. Sasadeusz J. J., Sacks S. L. Systemic antivirals in herpesvirus infections. Dermatol Clin. 1993 Jan;11(1):171–185. [PubMed] [Google Scholar]
  29. Trannoy E., Berger R., Holländer G., Bailleux F., Heimendinger P., Vuillier D., Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000 Feb 25;18(16):1700–1706. doi: 10.1016/s0264-410x(99)00510-1. [DOI] [PubMed] [Google Scholar]
  30. Tyring S., Barbarash R. A., Nahlik J. E., Cunningham A., Marley J., Heng M., Jones T., Rea T., Boon R., Saltzman R. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15;123(2):89–96. doi: 10.7326/0003-4819-123-2-199507150-00002. [DOI] [PubMed] [Google Scholar]
  31. WEBER D. M., PELLECCHIA J. A. VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN. JAMA. 1965 May 10;192:572–573. doi: 10.1001/jama.1965.03080190138035. [DOI] [PubMed] [Google Scholar]
  32. White C. J., Kuter B. J., Hildebrand C. S., Isganitis K. L., Matthews H., Miller W. J., Provost P. J., Ellis R. W., Gerety R. J., Calandra G. B. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991 May;87(5):604–610. [PubMed] [Google Scholar]
  33. Wise R. P., Salive M. E., Braun M. M., Mootrey G. T., Seward J. F., Rider L. G., Krause P. R. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000 Sep 13;284(10):1271–1279. doi: 10.1001/jama.284.10.1271. [DOI] [PubMed] [Google Scholar]
  34. Wood M. J., Johnson R. W., McKendrick M. W., Taylor J., Mandal B. K., Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994 Mar 31;330(13):896–900. doi: 10.1056/NEJM199403313301304. [DOI] [PubMed] [Google Scholar]
  35. Wood M. J., Ogan P. H., McKendrick M. W., Care C. D., McGill J. I., Webb E. M. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med. 1988 Aug 29;85(2A):79–83. [PubMed] [Google Scholar]
  36. de Miranda P., Burnette T. C. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab Dispos. 1994 Jan-Feb;22(1):55–59. [PubMed] [Google Scholar]
  37. van den Broek P. J., van der Meer J. W., Mulder J. D., Versteeg J., Mattie H. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection. 1984 Sep-Oct;12(5):338–341. doi: 10.1007/BF01651148. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES